FDA Issues CRL for Sotorasib in Advanced/Metastatic KRAS G12C+ NSCLC

1 year ago 48

A review from the FDA confirms the dose comparison post-marketing requirement that was detailed at the time of sotorasib’s accelerated approval for those with KRAS G12C–mutated non–small cell lung cancer.

1. Homepage
2. Lung Cancer
3. FDA Issues CRL for Sotorasib in Advanced/Metastatic KRAS G12C+ NSCLC